Short Interest Filing: Could Anthera Pharmaceuticals Incorporated (NASDAQ:ANTH) Skyrocket? The Stock Has Too Many Sellers

November 24, 2016 - By Linda Rogers   ·   0 Comments

Short Interest Filing: Could Anthera Pharmaceuticals Incorporated (NASDAQ:ANTH) Skyrocket? The Stock Has Too Many Sellers

The stock of Anthera Pharmaceuticals Incorporated (NASDAQ:ANTH) registered an increase of 12.77% in short interest. ANTH’s total short interest was 5.63 million shares in November as published by FINRA. Its up 12.77% from 4.99 million shares, reported previously. With 626,700 shares average volume, it will take short sellers 9 days to cover their ANTH’s short positions. The short interest to Anthera Pharmaceuticals Incorporated’s float is 16.68%. The stock closed at $1.81 during the last session. It is down 57.61% since April 22, 2016 and is downtrending. It has underperformed by 63.02% the S&P500.

Anthera Pharmaceuticals, Inc. is a biopharmaceutical firm focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The company has a market cap of $75.94 million. The Firm has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod. It currently has negative earnings. Sollpura is a non-porcine investigational Pancreatic Enzyme Replacement Therapy (PERT) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (EPI), often seen in patients with cystic fibrosis and other conditions.

Insitutional Activity: The institutional sentiment decreased to 1 in 2016 Q2. Its down 0.70, from 1.7 in 2016Q1. The ratio worsened, as 6 funds sold all Anthera Pharmaceuticals Inc shares owned while 14 reduced positions. 5 funds bought stakes while 29 increased positions. They now own 22.69 million shares or 1.80% less from 23.11 million shares in 2016Q1.
Jacobs Levy Equity Mgmt last reported 82,175 shares in the company. State Street has 792,859 shares for 0% of their US portfolio. Citigroup Inc holds 0% or 8,854 shares in its portfolio. Geode Cap Ltd accumulated 245,258 shares or 0% of the stock. Wexford Capital Ltd Partnership has 0.08% invested in the company for 145,622 shares. Millennium Mgmt Ltd Liability Co holds 0% of its portfolio in Anthera Pharmaceuticals Inc (NASDAQ:ANTH) for 64,569 shares. Boothbay Fund Mngmt Ltd Liability Com has invested 0.02% of its portfolio in Anthera Pharmaceuticals Inc (NASDAQ:ANTH). The Illinois-based Hightower Advsr Ltd Liability Company has invested 0% in Anthera Pharmaceuticals Inc (NASDAQ:ANTH). Blackrock Advsrs Ltd Co last reported 17,551 shares in the company. Sio Limited Liability has invested 4% of its portfolio in Anthera Pharmaceuticals Inc (NASDAQ:ANTH). Fmr Limited Liability holds 0% or 3.25M shares in its portfolio. Smith Asset Grp L P accumulated 49,120 shares or 0% of the stock. Proshare Advisors Lc has invested 0% of its portfolio in Anthera Pharmaceuticals Inc (NASDAQ:ANTH). Ny State Common Retirement Fund holds 38,000 shares or 0% of its portfolio. Moreover, California Public Employees Retirement Systems has 0% invested in Anthera Pharmaceuticals Inc (NASDAQ:ANTH) for 102,125 shares.

Anthera Pharmaceuticals Inc (NASDAQ:ANTH) Ratings Coverage

Out of 4 analysts covering Anthera Pharmaceuticals (NASDAQ:ANTH), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Anthera Pharmaceuticals has been the topic of 7 analyst reports since August 13, 2015 according to StockzIntelligence Inc. The firm earned “Buy” rating on Friday, July 8 by H.C. Wainwright. The firm earned “Buy” rating on Friday, February 19 by Jefferies. Citigroup initiated Anthera Pharmaceuticals Inc (NASDAQ:ANTH) rating on Thursday, September 17. Citigroup has “Buy” rating and $15 price target. Suntrust Robinson initiated the stock with “Buy” rating in Wednesday, September 9 report. The rating was initiated by SunTrust on Wednesday, September 9 with “Buy”. Zacks upgraded Anthera Pharmaceuticals Inc (NASDAQ:ANTH) on Thursday, August 13 to “Hold” rating.

ANTH Company Profile

Anthera Pharmaceuticals, Inc. (Anthera), incorporated on October 9, 2004, is a biopharmaceutical firm focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Firm has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod. Sollpura is a non-porcine investigational Pancreatic Enzyme Replacement Therapy (PERT) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (EPI), often seen in patients with cystic fibrosis and other conditions. Blisibimod targets B-cell activating factor (BAFF), which has been shown to be elevated in a range of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), or lupus, Immunoglobulin A nephropathy (IgA) nephropathy, lupus nephritis and others.

More news for Anthera Pharmaceuticals Inc (NASDAQ:ANTH) were recently published by: 247Wallst.com, which released: “Anthera Pharmaceuticals Slides on Missed Late Stage Results” on November 10, 2016. Seekingalpha.com‘s article titled: “Anthera Pharmaceuticals: Buy Low Opportunity On Potential Drug Approval” and published on February 02, 2016 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Linda Rogers

Tags: , ,


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>